LifeStance Health Group (NASDAQ:LFST) Announces Quarterly Earnings Results

LifeStance Health Group (NASDAQ:LFST) announced its earnings results on Thursday. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03, Briefing.com reports. The business had revenue of $403.48 million for the quarter, compared to analysts’ expectations of $387.46 million. LifeStance Health Group had a return on equity of 1.55% and a net margin of 1.55%.The business’s revenue for the quarter was up 21.2% compared to the same quarter last year.

Here are the key takeaways from LifeStance Health Group’s conference call:

• Q1 outperformance: Revenue grew 21% to $403M and adjusted EBITDA rose 48% to $51M, and management raised full‑year guidance to $1.64–$1.68B revenue and $200–$220M adjusted EBITDA while returning $49M in buybacks and ending the quarter with $195M cash.
• Clinician scale and productivity: LifeStance added 309 clinicians to reach 8,349 (11% growth), with visits up 18% to 2.5M and visits per average clinician improving 7% year‑over‑year, driven by durable productivity initiatives.
• Technology and AI focus: The company is deploying AI tools (scheduling, documentation, RPA) to improve access and efficiency and plans a new EHR implementation beginning this year with a 2027 transition to enable scalable AI integration and margin improvement.
• Growth strategy combines de novo expansion (guiding 20–30 new centers in 2026) with a renewed, disciplined tuck‑in M&A program — two small market entries closed in Q1 that establish new footprints for 2027+ growth.
• Clinical outcomes and patient satisfaction: Published outcomes from ~180,000 patients show ~75% achieved clinically significant improvements in anxiety/depression, and the network averages >4.7 stars across 575 centers, supporting differentiation with payers and referral partners.

LifeStance Health Group Stock Performance

LFST traded down $1.14 on Friday, reaching $7.72. 24,975,660 shares of the stock were exchanged, compared to its average volume of 4,897,221. The company’s 50-day moving average price is $6.80 and its 200 day moving average price is $6.68. LifeStance Health Group has a fifty-two week low of $3.74 and a fifty-two week high of $8.89. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.65 and a quick ratio of 1.65. The firm has a market capitalization of $2.99 billion, a PE ratio of 128.58 and a beta of 1.20.

LifeStance Health Group News Roundup

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: LifeStance posted a Q1 earnings beat and raised revenue guidance for both Q2 and full-year 2026, signaling stronger-than-expected business momentum.
• Positive Sentiment: BTIG increased its price target on LFST to $12 and reiterated a Buy rating, which may support investor confidence. Benzinga
• Positive Sentiment: Multiple brokerages now view LFST favorably, with consensus recommendations remaining in Buy territory.
• Neutral Sentiment: LifeStance announced a secondary offering of 35 million shares by existing stockholders; the company is not receiving proceeds, but the move can create trading overhang and volatility. GlobeNewswire
• Negative Sentiment: The secondary share sale may pressure the stock in the near term because it increases potential supply, even though LifeStance itself is not issuing new shares.

LifeStance Health Group announced that its Board of Directors has approved a share buyback program on Wednesday, February 25th that permits the company to buyback $100.00 million in shares. This buyback authorization permits the company to reacquire up to 3.6% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

Several analysts have issued reports on the company. Wall Street Zen raised LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Canaccord Genuity Group increased their target price on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. UBS Group increased their target price on LifeStance Health Group from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Barclays increased their target price on LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a research report on Friday, March 6th. Finally, Zacks Research raised LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $10.00.

Insider Transactions at LifeStance Health Group

In other LifeStance Health Group news, Director Robert Bessler sold 62,147 shares of LifeStance Health Group stock in a transaction dated Friday, April 24th. The stock was sold at an average price of $7.05, for a total transaction of $438,136.35. Following the completion of the sale, the director owned 1,274,448 shares of the company’s stock, valued at approximately $8,984,858.40. The trade was a 4.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Darren M. Black sold 4,314,939 shares of LifeStance Health Group stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $7.01, for a total value of $30,247,722.39. Following the sale, the director directly owned 29,209,776 shares of the company’s stock, valued at approximately $204,760,529.76. This represents a 12.87% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 4,389,939 shares of company stock valued at $30,775,881. 3.20% of the stock is currently owned by insiders.

Institutional Trading of LifeStance Health Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LFST. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in LifeStance Health Group by 62.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after acquiring an additional 1,839,465 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of LifeStance Health Group by 27.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after buying an additional 1,790,694 shares during the last quarter. Integral Health Asset Management LLC raised its stake in shares of LifeStance Health Group by 100.0% during the 4th quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company’s stock valued at $21,120,000 after buying an additional 1,500,000 shares during the last quarter. Barclays PLC raised its stake in shares of LifeStance Health Group by 74.7% during the 3rd quarter. Barclays PLC now owns 3,508,552 shares of the company’s stock valued at $19,297,000 after buying an additional 1,499,687 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of LifeStance Health Group during the 3rd quarter valued at about $7,637,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.